Published in Diabetologia on August 02, 2017
60 years of metformin use: a glance at the past and a look to the future. Diabetologia (2017) 0.75
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Diet rapidly and reproducibly alters the human gut microbiome. Nature (2013) 11.04
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 6.07
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature (2015) 4.98
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell (2013) 3.10
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature (2014) 3.09
Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 3.02
mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (2014) 2.78
Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med (2015) 2.70
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J (2014) 2.30
The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity (2015) 2.16
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A (2012) 2.11
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol (2015) 2.05
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med (2017) 2.05
Metformin: from mechanisms of action to therapies. Cell Metab (2014) 1.94
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med (2015) 1.91
Human gut microbes impact host serum metabolome and insulin sensitivity. Nature (2016) 1.85
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
Metformin as adjunct antituberculosis therapy. Sci Transl Med (2014) 1.40
Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab (2014) 1.34
Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 1.27
Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature (2016) 1.25
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell (2013) 1.13
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care (2015) 1.12
Metformin and the gastrointestinal tract. Diabetologia (2016) 1.06
Metformin as a Tool to Target Aging. Cell Metab (2016) 1.03
Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J (2015) 1.03
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? Cell Metab (2016) 0.95
Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res (2012) 0.92
Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol (2016) 0.92
Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care (2014) 0.91
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res (2016) 0.89
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metab (2016) 0.83
Metformin: historical overview. Diabetologia (2017) 0.81
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. JAMA Neurol (2016) 0.81
The effects of metformin compared to the effects of phenformin on the lactate production and the metabolism of isolated parenchymal rat liver cell. Acta Pharmacol Toxicol (Copenh) (1984) 0.79
Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. BMC Biol (2016) 0.78
Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res (2016) 0.78
Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab (2016) 0.77
The Microbiome and Risk for Obesity and Diabetes. JAMA (2017) 0.77
A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab (2017) 0.76
The Role of the Immune System in Metabolic Health and Disease. Cell Metab (2017) 0.76
Transporters Involved in Metformin Pharmacokinetics and Treatment Response. J Pharm Sci (2017) 0.76
Antimicrobial activities of biguanides. Ann N Y Acad Sci (1968) 0.76
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Clin Cancer Res (2017) 0.76
Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J Invest Dermatol (2017) 0.76
Metformin Suppresses Systemic Autoimmunity in Roquin(san/san) Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3. J Immunol (2017) 0.75
The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia (2017) 0.75
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest (2016) 0.75